Skip to main content
. 2013 Aug 7;19(23-24):2544–2552. doi: 10.1089/ten.tea.2012.0686

FIG. 3.

FIG. 3.

Transplants of 250 IEQ C57BL/6J islets into diabetic C57BL/6J mouse recipients. (A) Time to reversal to normoglycemia and (B) average nonfasting blood glucose of recipients following transplantation of 250 IEQ into the epididymal fat pad either free (gray line; n=7), within a PDMS scaffold (black line; n=8), or within a PDMS scaffold coloaded with fibrin/PDGF-BB (dashed black line; n=8). Reversal is defined as two consecutive readings <200 mg/dL. (C) Intravenous glucose tolerance test performed on functional graft recipients at 95 days post-transplant. Blood glucose measurements were collected at time points indicated, following injection of bolus glucose, for islets in either free (gray triangle; n=2), within a PDMS scaffold (black circle; n=3), or within a PDMS scaffold coloaded with fibrin/PDGF-BB (dashed black open circle; n=3). Implants were explanted between 110 and 150 days, where prompt reversal to a diabetic state was observed for all animals. Error bars=standard deviation. *Statistically significant difference in time to reversal from both scaffold only (p=0.009) and free (p=0.045). No difference was observed between free and scaffold-only groups (p=0.90).